(Reuters) – Purdue Pharma, the bankrupt maker of the OxyContin painkiller, on Monday obtained court approval to pay up to $7.1 million in incentive payments for five top executives if they meet certain goals, despite opposition from government lawyers.
U.S. Bankruptcy Judge Robert Drain in White Plains, New York signed off on the executive incentive plan at the conclusion of a virtual hearing.
His ruling comes about two weeks after he said he will approve Purdue’s reorganization plan, which rests on a $10 billion settlement of opioid-related litigation.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.